Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Pharmaceutical Co. Ltd.

www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

United States Approvals

Finance Watch: Atea Pharmaceuticals Raises $215m For COVID-19 Antiviral

Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.

Financing Coronavirus COVID-19

New Approvals In Spotlight As China Gears For National Congress

In a sign that attention in China may be shifting back to more routine regulatory work as the local coronavirus outbreak appears to recede, authorities have granted approvals to multiple new drugs for cancer and rare diseases, as the government gears up to hold its delayed annual congress in Beijing.

Approvals China

How Was Korea Different In Handling COVID-19 Situation?

South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.

South Korea Coronavirus COVID-19
See All

Company Information

UsernamePublicRestriction

Register